Welcome to our dedicated page for iBio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on iBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into iBio's regulatory disclosures and financial reporting.
iBio, Inc. entered into a securities purchase agreement with institutional investors for a private placement priced at-the-market, raising approximately $26 million in gross proceeds. The company agreed to sell 1,408,481 shares of common stock at $2.35 per share and issue pre-funded warrants to purchase up to 9,653,257 additional shares at an exercise price of $0.001 per share, with a purchase price of $2.349 per pre-funded warrant.
The closing is expected on or about January 13, 2026, and iBio plans to use the net proceeds to advance its preclinical cardiometabolic pipeline, including IBIO-610, IBIO-600 and myostatin/activin A bispecific programs, as well as other preclinical assets, and for working capital and general corporate purposes. The company granted investors registration rights for resale of the shares and warrant shares and agreed to temporary restrictions on additional equity issuances and certain corporate actions until the resale registration statement becomes effective or 60 days after closing.
iBio, Inc. reported a stock option grant to a director on a Form 4. On 11/20/2025, the director received 13,500 stock options with an exercise price of $1 per share, expiring on 11/19/2035. These options vest pro rata on a monthly basis over twelve months starting on the grant date. Following this transaction, the director beneficially owns 13,500 derivative securities, held as a direct ownership position.
iBio, Inc. (IBIO) reported a routine insider equity grant on a Form 4. A company director received a stock option (right to buy) covering 13,500 shares of common stock on 11/20/2025 with an exercise price of $1 per share. The option expires on 11/19/2035, giving a long window to purchase shares at that price. These options vest on a pro rata monthly basis over twelve months starting from the grant date, meaning the director earns the right to exercise a portion of the option each month during the first year.
iBio, Inc. (IBIO) reported a director equity award on a Form 4. On 11/20/2025, the reporting person received a stock option grant covering 13,500 shares of iBio common stock. The options have an exercise price of $1 per share and an expiration date of 11/19/2035.
The filing states that these options vest on a pro rata basis each month over twelve months, starting on the grant date. Following this grant, the reporting person beneficially owns 13,500 derivative securities directly in the form of these options.
iBio, Inc. (IBIO) disclosed that a director received a new stock option grant reported on Form 4. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1 per share. These options vest on a pro rata monthly basis over twelve months starting from the grant date, aligning the director’s compensation with the company’s share performance over the coming year. The options have an expiration date of 11/19/2035 and are held as direct ownership by the reporting person.
iBio, Inc. (IBIO) reported that one of its directors received a new stock option grant. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share.
These options vest pro rata on a monthly basis over twelve months starting from the grant date, meaning the director earns a portion of the options each month during the first year. The options have an expiration date of 11/19/2035, giving a long period in which they may be exercised, subject to the vesting schedule and any applicable company or regulatory requirements.
iBio, Inc. reported a stock-based compensation grant to one of its directors. On 11/20/2025, the director received a stock option to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share. The option becomes exercisable gradually, vesting in equal monthly installments over twelve months starting on the grant date, and expires on 11/19/2035 if not exercised. The filing indicates the director holds these options directly.
iBio, Inc. reported the results of its Annual Meeting of Stockholders held on November 20, 2025. Stockholders representing 10,566,364 shares were present in person or by proxy, constituting a quorum. Two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, were elected to three-year terms expiring at the 2028 Annual Meeting.
Stockholders ratified the appointment of Grassi & Co., CPAs, P.C. as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 9,912,837 votes for and 594,576 against. They also approved, on an advisory basis, the executive compensation program, with 4,392,583 votes for and 403,278 against.
In addition, stockholders approved holding future advisory votes on executive compensation every year, with 4,290,210 votes favoring a one-year frequency. Consistent with this vote and the Board’s recommendation, the Company will conduct an annual advisory say-on-pay vote until the next required vote on frequency.
iBio, Inc. filed a Form 8-K to announce that it has updated its corporate presentation. The new investor presentation is furnished as Exhibit 99.1 and is intended for use in meetings with investors, analysts and other stakeholders. The presentation includes forward-looking statements covered by “safe harbor” language under the Private Securities Litigation Reform Act of 1995. iBio notes it has no obligation to update the information in the presentation, although it may choose to do so through future public disclosures.
iBio, Inc. filed an amended Form 10-Q/A mainly to correct the CEO Section 906 certification language in Exhibit 32.1; all financial and business disclosures from the original quarterly report for the three months ended September 30, 2025 remain unchanged.
The company is a preclinical biotech using AI and machine learning to design precision antibodies for obesity and cardiometabolic diseases, with lead candidate IBIO-610, a long-acting Activin E–inhibiting antibody, targeted for first human trials in early 2027. For the quarter, iBio generated $100,000 of collaboration revenue and recorded a net loss of $5.7 million, or $0.11 per share, as R&D spending rose to support its pipeline. A recent underwritten public offering and related pre-funded warrants provided approximately $50 million of gross proceeds, lifting cash, cash equivalents and investments in debt securities to about $49.6 million, which management believes is sufficient to fund operations for at least 12 months from the filing date.